Demographic and clinical characteristics of APL cases stratified by CD95 −1377 genotype
| . | Total, N (%) . | CD95 −1377 status . | P . | |
|---|---|---|---|---|
| GG, N (%) . | GA + AA, N (%) . | |||
| Total | 231 | 187 | 44 | |
| Sex | ||||
| Female | 124 (54) | 102 (55) | 22 (50) | .6 |
| Male | 107 (46) | 85 (45) | 22 (50) | |
| Age, y | ||||
| 0-14 | 2 (1) | 1 (0) | 1 (2) | .2* |
| 15-29 | 65 (28) | 56 (30) | 9 (20) | |
| 30-39 | 57 (25) | 46 (25) | 11 (25) | |
| 40-49 | 51 (22) | 41 (22) | 10 (23) | |
| 50-59 | 48 (21) | 38 (20) | 10 (23) | |
| ≥ 60 | 8 (3) | 5 (3) | 3 (7) | |
| Median (range) | 38 (1-63) | 38 (1-62) | 40 (13-61) | |
| Diagnosis | ||||
| De novo | 223 (97) | 182 (97) | 41 (93) | .18 |
| Secondary | 8 (3) | 5 (3) | 3 (7) | |
| WHO performance status | ||||
| 0 | 149 (65) | 122 (65) | 27 (61) | .8* |
| 1 | 63 (27) | 49 (26) | 14 (32) | |
| 2 | 10 (4) | 9 (5) | 1 (2) | |
| 3 | 6 (3) | 5 (3) | 1 (2) | |
| 4 | 3 (1) | 2 (1) | 1 (2) | |
| WBC, × 109 L−1 | ||||
| < 10 | 165 (72) | 131 (70) | 34 (79) | .15* |
| 10-19.9 | 22 (10) | 15 (8) | 6 (14) | |
| 20-49.9 | 21 (9) | 20 (11) | 1 (2) | |
| 50-99.9 | 16 (7) | 17 (9) | 0 (0) | |
| ≥ 100 | 5 (2) | 3 (2) | 2 (5) | |
| Median (range) | 3 (0.2-195) | 3.3 (0.2-140) | 2.1 (0.6-195) | |
| Platelets, × 109 L−1 | ||||
| < 10 | 14 (6) | 12 (6) | 2 (5) | .15* |
| 10-19.9 | 75 (34) | 62 (33) | 13 (31) | |
| 20-49.9 | 102 (44) | 83 (45) | 19 (45) | |
| 50-99.9 | 23 (10) | 19 (10) | 4 (10) | |
| ≥ 100 | 13 (6) | 9 (5) | 4 (10) | |
| Median (range) | 23 (5-232) | 22 (6-232) | 26 (5-146) | |
| . | Total, N (%) . | CD95 −1377 status . | P . | |
|---|---|---|---|---|
| GG, N (%) . | GA + AA, N (%) . | |||
| Total | 231 | 187 | 44 | |
| Sex | ||||
| Female | 124 (54) | 102 (55) | 22 (50) | .6 |
| Male | 107 (46) | 85 (45) | 22 (50) | |
| Age, y | ||||
| 0-14 | 2 (1) | 1 (0) | 1 (2) | .2* |
| 15-29 | 65 (28) | 56 (30) | 9 (20) | |
| 30-39 | 57 (25) | 46 (25) | 11 (25) | |
| 40-49 | 51 (22) | 41 (22) | 10 (23) | |
| 50-59 | 48 (21) | 38 (20) | 10 (23) | |
| ≥ 60 | 8 (3) | 5 (3) | 3 (7) | |
| Median (range) | 38 (1-63) | 38 (1-62) | 40 (13-61) | |
| Diagnosis | ||||
| De novo | 223 (97) | 182 (97) | 41 (93) | .18 |
| Secondary | 8 (3) | 5 (3) | 3 (7) | |
| WHO performance status | ||||
| 0 | 149 (65) | 122 (65) | 27 (61) | .8* |
| 1 | 63 (27) | 49 (26) | 14 (32) | |
| 2 | 10 (4) | 9 (5) | 1 (2) | |
| 3 | 6 (3) | 5 (3) | 1 (2) | |
| 4 | 3 (1) | 2 (1) | 1 (2) | |
| WBC, × 109 L−1 | ||||
| < 10 | 165 (72) | 131 (70) | 34 (79) | .15* |
| 10-19.9 | 22 (10) | 15 (8) | 6 (14) | |
| 20-49.9 | 21 (9) | 20 (11) | 1 (2) | |
| 50-99.9 | 16 (7) | 17 (9) | 0 (0) | |
| ≥ 100 | 5 (2) | 3 (2) | 2 (5) | |
| Median (range) | 3 (0.2-195) | 3.3 (0.2-140) | 2.1 (0.6-195) | |
| Platelets, × 109 L−1 | ||||
| < 10 | 14 (6) | 12 (6) | 2 (5) | .15* |
| 10-19.9 | 75 (34) | 62 (33) | 13 (31) | |
| 20-49.9 | 102 (44) | 83 (45) | 19 (45) | |
| 50-99.9 | 23 (10) | 19 (10) | 4 (10) | |
| ≥ 100 | 13 (6) | 9 (5) | 4 (10) | |
| Median (range) | 23 (5-232) | 22 (6-232) | 26 (5-146) | |
WBC (n = 229) and platelet (n = 227) data not available on all patients.
Test for trend.